363 related articles for article (PubMed ID: 30030174)
1. Molecular and cellular mechanisms for zoledronic acid-loaded magnesium-strontium alloys to inhibit giant cell tumors of bone.
Li M; Wang W; Zhu Y; Lu Y; Wan P; Yang K; Zhang Y; Mao C
Acta Biomater; 2018 Sep; 77():365-379. PubMed ID: 30030174
[TBL] [Abstract][Full Text] [Related]
2. Regulation of osteogenesis and osteoclastogenesis by zoledronic acid loaded on biodegradable magnesium-strontium alloy.
Li M; Wan P; Wang W; Yang K; Zhang Y; Han Y
Sci Rep; 2019 Jan; 9(1):933. PubMed ID: 30700724
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib Inhibits Giant Cell Tumor of Bone through Induction of Cell Apoptosis and Inhibition of Osteoclast Recruitment, Giant Cell Formation, and Bone Resorption.
Xu L; Luo J; Jin R; Yue Z; Sun P; Yang Z; Yang X; Wan W; Zhang J; Li S; Liu M; Xiao J
Mol Cancer Ther; 2016 May; 15(5):854-65. PubMed ID: 26861247
[TBL] [Abstract][Full Text] [Related]
4. In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid.
Shibuya I; Takami M; Miyamoto A; Karakawa A; Dezawa A; Nakamura S; Kamijo R
Pathol Oncol Res; 2019 Jan; 25(1):409-419. PubMed ID: 29159783
[TBL] [Abstract][Full Text] [Related]
5. Dual modulation of bone formation and resorption with zoledronic acid-loaded biodegradable magnesium alloy implants improves osteoporotic fracture healing: An in vitro and in vivo study.
Li G; Zhang L; Wang L; Yuan G; Dai K; Pei J; Hao Y
Acta Biomater; 2018 Jan; 65():486-500. PubMed ID: 29079514
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant Zoledronic Acid in High-Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial.
Lipplaa A; Kroep JR; van der Heijden L; Jutte PC; Hogendoorn PCW; Dijkstra S; Gelderblom H
Oncologist; 2019 Jul; 24(7):889-e421. PubMed ID: 31040253
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone.
Balke M; Campanacci L; Gebert C; Picci P; Gibbons M; Taylor R; Hogendoorn P; Kroep J; Wass J; Athanasou N
BMC Cancer; 2010 Aug; 10():462. PubMed ID: 20799989
[TBL] [Abstract][Full Text] [Related]
8. Nitrogen-containing bisphosphonate-loaded micro-arc oxidation coating for biodegradable magnesium alloy pellets inhibits osteosarcoma through targeting of the mevalonate pathway.
Li M; Yao M; Wang W; Wan P; Chu X; Zheng Y; Yang K; Zhang Y
Acta Biomater; 2021 Feb; 121():682-694. PubMed ID: 33220487
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue.
Lau YS; Sabokbar A; Gibbons CL; Giele H; Athanasou N
Hum Pathol; 2005 Sep; 36(9):945-54. PubMed ID: 16153456
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms.
Quinn JE; Brown LG; Zhang J; Keller ET; Vessella RL; Corey E
Prostate Cancer Prostatic Dis; 2005; 8(3):253-9. PubMed ID: 15999121
[TBL] [Abstract][Full Text] [Related]
11. Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model.
Qiao H; Wang TY; Yu ZF; Han XG; Liu XQ; Wang YG; Fan QM; Qin A; Tang TT
Cell Death Dis; 2016 Feb; 7(2):e2094. PubMed ID: 26866274
[TBL] [Abstract][Full Text] [Related]
12. Current concepts in the treatment of giant cell tumour of bone.
van der Heijden L; Dijkstra S; van de Sande M; Gelderblom H
Curr Opin Oncol; 2020 Jul; 32(4):332-338. PubMed ID: 32541321
[TBL] [Abstract][Full Text] [Related]
13. Zoledronic Acid Enhanced the Antitumor Effect of Cisplatin on Orthotopic Osteosarcoma by ROS-PI3K/AKT Signaling and Attenuated Osteolysis.
Liu L; Geng H; Mei C; Chen L
Oxid Med Cell Longev; 2021; 2021():6661534. PubMed ID: 33859780
[TBL] [Abstract][Full Text] [Related]
14. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.
Mundy GR; Yoneda T; Hiraga T
Semin Oncol; 2001 Apr; 28(2 Suppl 6):35-44. PubMed ID: 11346863
[TBL] [Abstract][Full Text] [Related]
15. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
[TBL] [Abstract][Full Text] [Related]
16. Updated concepts in treatment of giant cell tumor of bone.
van der Heijden L; Lipplaa A; van Langevelde K; Bovée JVMG; van de Sande MAJ; Gelderblom H
Curr Opin Oncol; 2022 Jul; 34(4):371-378. PubMed ID: 35837707
[TBL] [Abstract][Full Text] [Related]
17. Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone.
Li X; Liao J; Park SI; Koh AJ; Sadler WD; Pienta KJ; Rosol TJ; McCauley LK
Bone; 2011 Jun; 48(6):1354-61. PubMed ID: 21419883
[TBL] [Abstract][Full Text] [Related]
18. Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review.
Wang L; Fang D; Xu J; Luo R
BMC Cancer; 2020 Nov; 20(1):1059. PubMed ID: 33143662
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration.
Odri G; Kim PP; Lamoureux F; Charrier C; Battaglia S; Amiaud J; Heymann D; Gouin F; Redini F
BMC Cancer; 2014 Mar; 14():169. PubMed ID: 24612486
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic Acid Inhibits the RhoA-mediated Amoeboid Motility of Prostate Cancer Cells.
Pietrovito L; Comito G; Parri M; Giannoni E; Chiarugi P; Taddei ML
Curr Cancer Drug Targets; 2019; 19(10):807-816. PubMed ID: 30648509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]